Abstract
Introduction/Aims: The benefits of long-term human albumin (HA) administration to patients with cirrhosis and ascites seen in the ANSWER trial1 were associated to a significant increase of serum albumin concentration (SA). A post-hoc analysis2 showed that survival paralleled with on-treatment SA at month 1 and optimal results follow the achievement of normal SA. This study aimed to determine whether patients randomized to the standard medical treatment plus HA arm (SMT+HA) in the ANSWER trial who failed to normalize on-treatment SA (≥3.5g/dL) at month 1 have any advantage as compared to those receiving SMT alone.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
